10x Genomics (TXG)
(Delayed Data from NSDQ)
$27.59 USD
+0.69 (2.57%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.92 +0.33 (1.20%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth B Momentum B VGM
Income Statements
Fiscal Year end for 10x Genomics falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 619 | 516 | 490 | 299 | 246 |
Cost Of Goods | 209 | 120 | 74 | 58 | 61 |
Gross Profit | 409 | 396 | 416 | 240 | 185 |
Selling & Adminstrative & Depr. & Amort Expenses | 675 | 564 | 469 | 775 | 215 |
Income After Depreciation & Amortization | -265 | -168 | -52 | -534 | -31 |
Non-Operating Income | 17 | 6 | -1 | 1 | 3 |
Interest Expense | 0 | 0 | 1 | 2 | 3 |
Pretax Income | -249 | -162 | -54 | -534 | -31 |
Income Taxes | 6 | 4 | 5 | 8 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -255 | -166 | -58 | -543 | -31 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -255 | -166 | -58 | -543 | -31 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -222 | -134 | -24 | -515 | -24 |
Depreciation & Amortization (Cash Flow) | 44 | 34 | 28 | 19 | 7 |
Income After Depreciation & Amortization | -265 | -168 | -52 | -534 | -31 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 117.17 | 113.86 | 110.35 | 101.15 | 39.09 |
Diluted EPS Before Non-Recurring Items | -1.66 | -1.46 | -0.53 | -0.95 | -0.80 |
Diluted Net EPS (GAAP) | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 |
Fiscal Year end for 10x Genomics falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 183.98 | 153.64 | 146.82 | 134.29 |
Cost Of Goods | NA | 68.20 | 58.12 | 47.21 | 35.90 |
Gross Profit | NA | 115.78 | 95.53 | 99.61 | 98.39 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 170.96 | 190.33 | 162.97 | 150.38 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -55.18 | -94.80 | -63.36 | -51.99 |
Non-Operating Income | NA | 8.60 | 3.05 | 2.60 | 2.35 |
Interest Expense | NA | 0.01 | 0.00 | 0.01 | 0.02 |
Pretax Income | NA | -46.60 | -91.74 | -60.77 | -49.65 |
Income Taxes | NA | 2.35 | 1.24 | 1.65 | 1.09 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -48.95 | -92.99 | -62.41 | -50.75 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -48.95 | -92.99 | -62.41 | -50.75 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 118.57 | 117.73 | 116.71 | 115.62 |
Diluted EPS Before Non-Recurring Items | NA | -0.41 | -0.51 | -0.53 | -0.44 |
Diluted Net EPS (GAAP) | NA | -0.42 | -0.79 | -0.53 | -0.44 |